Vittoria Biotherapeutics utilizes its proprietary Senza5 platform to develop next-generation autologous CAR T-cell therapies that enhance efficacy and safety while reducing manufacturing time to five days. The company targets the challenges of low potency and accessibility in current immunotherapy treatments for oncology and immunology.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VFFounders
Product
Problem
Current autologous CAR T-cell therapies face challenges related to efficacy, safety, and accessibility, often requiring lengthy manufacturing processes and exhibiting variable potency. These limitations hinder the widespread adoption and effectiveness of immunotherapy treatments for oncology and immunology.
Solution
Vittoria Biotherapeutics is developing next-generation autologous CAR T-cell therapies designed to improve efficacy, enhance safety, and reduce manufacturing time. Their proprietary Senza5 platform modulates CD5 signaling and employs a novel 5-day manufacturing process to achieve superior potency. This approach aims to address unmet clinical needs in oncology and immunology by creating more effective and accessible immunotherapies.
Target Audience
The primary target audience includes patients with T-cell lymphomas and other cancers or immunological disorders who can benefit from more effective and accessible CAR T-cell therapies.
Features
- Senza5 platform technology for enhanced CAR T-cell engineering
- CD5 signaling modulation for improved T-cell activity
- Rapid 5-day manufacturing process
- Autologous CAR T-cell therapies for personalized treatment
- VIPER-101 Phase 1 clinical trial for T-cell lymphoma (NCT06420089)